Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Human respiratory epithelial cells acquire a long-lasting antiviral condition when exposed to interferon beta

Giel Gaajetaan, Gert Grauls, Catrien Bruggeman, Frank Stassen
European Respiratory Journal 2011 38: 198; DOI:
Giel Gaajetaan
Medical Microbiology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gert Grauls
Medical Microbiology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catrien Bruggeman
Medical Microbiology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Stassen
Medical Microbiology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Type I interferons (IFNs) induce strong antiviral effects and are therefore attractive to prevent seasonal respiratory infections or reduce the incidence of virus-mediated exacerbation in COPD patients. Yet, clinical application of type I IFNs is hindered due to significant side effects observed during repetitive use. In this study we investigate the duration of protection, mediated by prophylactic IFNbeta, against a human rhinovirus (HRV) infection.

Human respiratory epithelial (A549) cells were exposed for 18 hours to various concentrations (31-500 IU/ml) of IFNbeta. Then, IFNbeta was either removed or maintained in the supernatant for the rest of the experiment. Next, cells were infected with HRV-1B (MOI 0.1) at t = 0, 24, 48, 72 or 168 hours after the initial exposure to IFNbeta. At 48 hours post infection, the protective effect of IFNbeta on HRV-induced cell death was determined by a colorimetric assay. RT-qPCR and plaque assay were used to determine HRV infection.

In the continuous presence of IFNbeta, 90-100% of A549 cells were protected against HRV-induced cell death at every time point and at all IFNbeta concentrations. This strong protective effect was confirmed by RT-qPCR and plaque assay. Alternatively, when IFNbeta was removed, cell death increased with time and in dose-dependent way. Nevertheless, at 168h post IFNbeta stimulation (500IU/ml), still 75% of all cells were viable.

These data show that IFNbeta has not only a strong, but also long-lasting protective effect against HRV-1B. This opens new opportunities for prophylactic treatment of viral respiratory infections without the risk of side effects often seen after repetitive and systemic use.

  • © 2011 ERS
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human respiratory epithelial cells acquire a long-lasting antiviral condition when exposed to interferon beta
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human respiratory epithelial cells acquire a long-lasting antiviral condition when exposed to interferon beta
Giel Gaajetaan, Gert Grauls, Catrien Bruggeman, Frank Stassen
European Respiratory Journal Sep 2011, 38 (Suppl 55) 198;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Human respiratory epithelial cells acquire a long-lasting antiviral condition when exposed to interferon beta
Giel Gaajetaan, Gert Grauls, Catrien Bruggeman, Frank Stassen
European Respiratory Journal Sep 2011, 38 (Suppl 55) 198;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Predictors of poor outcome in severe hospitalised COPD exacerbations
  • Metagenomic analysis of lower airway microbial diversity in patients with chronic pulmonary disease
  • Value of galactomannan in bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease
Show more 45. Mechanisms and outcomes of infective exacerbations of COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society